195 related articles for article (PubMed ID: 21768280)
1. Importance of antibodies to lipopolysaccharide in natural and vaccine-induced serum bactericidal activity against Neisseria meningitidis group B.
Schmiel DH; Moran EE; Keiser PB; Brandt BL; Zollinger WD
Infect Immun; 2011 Oct; 79(10):4146-56. PubMed ID: 21768280
[TBL] [Abstract][Full Text] [Related]
2. Susceptibility of Meningococcal Strains Responsible for Two Serogroup B Outbreaks on U.S. University Campuses to Serum Bactericidal Activity Elicited by the MenB-4C Vaccine.
Rossi R; Beernink PT; Giuntini S; Granoff DM
Clin Vaccine Immunol; 2015 Dec; 22(12):1227-34. PubMed ID: 26424832
[TBL] [Abstract][Full Text] [Related]
3. The adhesin complex protein (ACP) of Neisseria meningitidis is a new adhesin with vaccine potential.
Hung MC; Heckels JE; Christodoulides M
mBio; 2013 Feb; 4(2):. PubMed ID: 23443003
[TBL] [Abstract][Full Text] [Related]
4. Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage.
Frosi G; Biolchi A; Lo Sapio M; Rigat F; Gilchrist S; Lucidarme J; Findlow J; Borrow R; Pizza M; Giuliani MM; Medini D
Vaccine; 2013 Oct; 31(43):4968-74. PubMed ID: 23954380
[TBL] [Abstract][Full Text] [Related]
5. A putative amino acid ABC transporter substrate-binding protein, NMB1612, from Neisseria meningitidis, induces murine bactericidal antibodies against meningococci expressing heterologous NMB1612 proteins.
Hung MC; Humbert MV; Laver JR; Phillips R; Heckels JE; Christodoulides M
Vaccine; 2015 Aug; 33(36):4486-94. PubMed ID: 26207592
[TBL] [Abstract][Full Text] [Related]
6. Agonists of Toll-like receptors 3, 4, 7, and 9 are candidates for use as adjuvants in an outer membrane vaccine against Neisseria meningitidis serogroup B.
Fransen F; Boog CJ; van Putten JP; van der Ley P
Infect Immun; 2007 Dec; 75(12):5939-46. PubMed ID: 17908810
[TBL] [Abstract][Full Text] [Related]
7. Naturally-occurring human serum antibodies to inner core lipopolysaccharide epitopes of Neisseria meningitidis protect against invasive meningococcal disease caused by isolates displaying homologous inner core structures.
Jäkel A; Plested JS; Hoe JC; Makepeace K; Gidney MA; Lacelle S; St Michael F; Cox AD; Richards JC; Moxon ER
Vaccine; 2008 Dec; 26(51):6655-63. PubMed ID: 18835574
[TBL] [Abstract][Full Text] [Related]
8. Age-related disparity in functional activities of human group C serum anticapsular antibodies elicited by meningococcal polysaccharide vaccine.
Harris SL; King WJ; Ferris W; Granoff DM
Infect Immun; 2003 Jan; 71(1):275-86. PubMed ID: 12496177
[TBL] [Abstract][Full Text] [Related]
9. Strategies for development of universal vaccines against meningococcal serogroup B disease: the most promising options and the challenges evaluating them.
Holst J
Hum Vaccin; 2007; 3(6):290-4. PubMed ID: 17712231
[TBL] [Abstract][Full Text] [Related]
10. Cross-reactivity of antibodies against PorA after vaccination with a meningococcal B outer membrane vesicle vaccine.
Vermont CL; van Dijken HH; Kuipers AJ; van Limpt CJ; Keijzers WC; van der Ende A; de Groot R; van Alphen L; van den Dobbelsteen GP
Infect Immun; 2003 Apr; 71(4):1650-5. PubMed ID: 12654777
[TBL] [Abstract][Full Text] [Related]
11. The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB.
Martin DR; Ruijne N; McCallum L; O'Hallahan J; Oster P
Clin Vaccine Immunol; 2006 Apr; 13(4):486-91. PubMed ID: 16603616
[TBL] [Abstract][Full Text] [Related]
12. Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: a phase III, randomized, multicentre, lot-to-lot consistency study.
Perrett KP; McVernon J; Richmond PC; Marshall H; Nissen M; August A; Percell S; Toneatto D; Nolan T
Vaccine; 2015 Sep; 33(39):5217-24. PubMed ID: 26232542
[TBL] [Abstract][Full Text] [Related]
13. New zealand epidemic strain meningococcal B outer membrane vesicle vaccine in children aged 16-24 months.
Wong S; Lennon D; Jackson C; Stewart J; Reid S; Crengle S; Tilman S; Aaberge I; O'Hallahan J; Oster P; Mulholland K; Martin D
Pediatr Infect Dis J; 2007 Apr; 26(4):345-50. PubMed ID: 17414400
[TBL] [Abstract][Full Text] [Related]
14. Serum Bactericidal Antibody Responses of Students Immunized With a Meningococcal Serogroup B Vaccine in Response to an Outbreak on a University Campus.
Lujan E; Winter K; Rovaris J; Liu Q; Granoff DM
Clin Infect Dis; 2017 Oct; 65(7):1112-1119. PubMed ID: 28582542
[TBL] [Abstract][Full Text] [Related]
15. Candidacy of LPS-based glycoconjugates to prevent invasive meningococcal disease: developmental chemistry and investigation of immunological responses following immunization of mice and rabbits.
Cox AD; Zou W; Gidney MA; Lacelle S; Plested JS; Makepeace K; Wright JC; Coull PA; Moxon ER; Richards JC
Vaccine; 2005 Oct; 23(43):5045-54. PubMed ID: 16046037
[TBL] [Abstract][Full Text] [Related]
16. Persisting immune responses indicating long-term protection after booster dose with meningococcal group B outer membrane vesicle vaccine.
Feiring B; Fuglesang J; Oster P; Naess LM; Helland OS; Tilman S; Rosenqvist E; Bergsaker MA; Nøkleby H; Aaberge IS
Clin Vaccine Immunol; 2006 Jul; 13(7):790-6. PubMed ID: 16829617
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of a Serogroup B and C Meningococcal Vaccine Developed in Cuba.
Ochoa-Azze RF; García-Imía L; Vérez-Bencomo V
MEDICC Rev; 2018 Jul; 20(3):22-29. PubMed ID: 31242158
[TBL] [Abstract][Full Text] [Related]
18. The role of anti-NHba antibody in bactericidal activity elicited by the meningococcal serogroup B vaccine, MenB-4C.
Partridge E; Lujan E; Giuntini S; Vu DM; Granoff DM
Vaccine; 2017 Jul; 35(33):4236-4244. PubMed ID: 28651840
[TBL] [Abstract][Full Text] [Related]
19. Enzyme linked immunosorbent assay (ELISA) for the detection of serum antibodies to the inner core lipopolysaccharide of Neisseria meningitidis group B.
Plested JS; Gidney MA; Coull PA; Griffiths HG; Herbert MA; Bird AG; Richards JC; Moxon ER
J Immunol Methods; 2000 Apr; 237(1-2):73-84. PubMed ID: 10725453
[TBL] [Abstract][Full Text] [Related]
20. A glycoconjugate vaccine for Neisseria meningitidis induces antibodies in human infants that afford protection against meningococcal bacteremia in a neonate rat challenge model.
Mountzouros KT; Belanger KA; Howell AP; Bixler GS; Madore DV
Infect Immun; 2002 Dec; 70(12):6576-82. PubMed ID: 12438327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
